Related Experiment Videos
Update on topical carbonic anhydrase inhibitors
1Mainz University-Hospital, Mainz, Germany. herkel@augen.klinik.uni-mainz.de
Current Opinion in Ophthalmology
|February 27, 2001
Summary
Topical carbonic anhydrase inhibitors like dorzolamide and brinzolamide effectively lower intraocular pressure for glaucoma treatment. While their efficacy is comparable to other agents, they may offer additional benefits through improved blood flow, though long-term impact requires further study.
Area of Science:
- Ophthalmology
- Pharmacology
Background:
- Topical carbonic anhydrase inhibitors (dorzolamide, brinzolamide) are established medical treatments for glaucoma.
- These agents inhibit carbonic anhydrase, an enzyme crucial for aqueous humor production, thereby reducing intraocular pressure.
Purpose of the Study:
- To evaluate the efficacy and characteristics of topical carbonic anhydrase inhibitors in glaucoma management.
- To compare their intraocular pressure-lowering activity with other glaucoma medications.
Main Methods:
- Review of existing data on dorzolamide and brinzolamide efficacy.
- Comparison of their intraocular pressure-lowering effects against other topical glaucoma treatments.
Main Results:
- Dorzolamide and brinzolamide demonstrate comparable intraocular pressure-lowering effects, similar to many other agents.
- Their efficacy does not match that of timolol or latanoprost but shows additivity with other topical treatments.
- Potential benefits include improved ocular blood flow, though long-term clinical significance is yet to be determined.
- Adverse effects are predominantly localized.
Conclusions:
- Topical carbonic anhydrase inhibitors are valuable additions to glaucoma therapy.
- Brinzolamide's more physiological pH may offer a local tolerability advantage.
- Further research is needed to confirm the long-term benefits of potential hemodynamic effects.